AstraZeneca's $34M Texas Settlement: What Pharma Support Services Mean for Prescribers

References

1. 1.Silverman, E. (2026, June 29). AstraZeneca to pay $34 million to settle kickback charges filed by Texas attorney general. STAT News. https://www.statnews.com/pharmalot/2026/06/29/astrazeneca-kickback-charges-texas-settlement/
2. 2.Sacks, C. A., Lee, C. C., Kesselheim, A. S., & Avorn, J. (2018). Medicare spending on brand-name combination medications vs their components. JAMA, 320(7), 650–656. https://doi.org/10.1001/jama.2018.11439
3. 3.Fugh-Berman, A., & Ahari, S. (2007). Following the script: How drug reps make friends and influence doctors. PLOS Medicine, 4(4), e150. https://doi.org/10.1371/journal.pmed.0040150
4. 4.Kesselheim, A. S., Mello, M. M., & Studdert, D. M. (2011). Strategies and practices in off-label marketing of pharmaceuticals: A retrospective analysis of whistleblower complaints. PLOS Medicine, 8(4), e1000431. https://doi.org/10.1371/journal.pmed.1000431
5. 5.U.S. Department of Health and Human Services, Office of Inspector General. (2023). OIG Work Plan: Pharmaceutical manufacturer patient support programs. HHS OIG. https://oig.hhs.gov/reports-and-publications/workplan/summary/wp-summary-0000706.asp
6. 6.Australian Health Practitioner Regulation Agency. (2020). Good medical practice: A code of conduct for doctors in Australia. Medical Board of Australia. https://www.medicalboard.gov.au/codes-guidelines-policies/code-of-conduct.aspx
7. 7.Hwang, T. J., Kesselheim, A. S., & Vokinger, K. N. (2019). Lifecycle regulation of pharmaceuticals and the public interest. JAMA, 321(20), 1969–1970. https://doi.org/10.1001/jama.2019.4262
8. 8.Rodwin, M. A. (2018). Attempts to redefine payments to physicians as educational or research: The pharmaceutical industry's response to charges of illegal kickbacks. Journal of Law, Medicine & Ethics, 46(2), 432–446. https://doi.org/10.1177/1073110518782955